Ann: Activities Update Qtr Ending June 2021 and Appendix 4C, page-26

Hi Candid,

OSX approved products are mostly in CMFT space which has a TAM of $1B.
The $100B refers to Orthopedics which OSX is still undergoing clinical trials for (long bone repair scaffolding).
Either way always good to take the TAM with a pinch of salt.

The reality of what is happening with the SP is due to the CEO selling shares, he has sold close to 40% of his holding since this floated in 2019.
We can speculate all day on why, though he has been with the company since 2015 (pre IPO), perhaps he decided it was time to materialize some profits while the SP was at record highs? It's disappointing but it is what it is.

I think holders and investors need to look at where does OSX fit in with peers?
If you look at the biotech space on the ASX and check which ones are revenue generating referenced across market cap sizes you will see OSX is undervalued at current prices, and don't forget to look at cash balance. I personally track every single BIOTECH on the ASX and can very easily see where OSX is across all 88 listed companies in this segment.

While I have significantly larger stake here and down about $25k, I do think there is a turn around coming once investors catch on.

Shame on the CEO & BoD yes. I am disappointed but it is what it is - the fundamentals have not changed, the product is still a strong product in it's niche and revenues as a whole are increasing on an annual basis. At ~$30M Enterprise value for an FDA approved product with various others in its pipeline, at the end of the day there is still value here.